Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo

Allergy and Asthma Proceedings

Volumn 27, Issue 3, 2006, Pages 202-207

  Hampel Jr , Frank C ^a,g   Ratner, Paul H ^b   Amar, Niran J ^c   Van Bavel, Julius H ^d   Mohar, Dale ^e   Fairchild, Carol J ^f   Wall, G Michael ^f   Brubaker, Michael J ^f   Drake, Margaret ^f   Crenshaw, Krista M ^f  

^a Central Texas Health Research   (United States)

^b Sylvana Research   (United States)

^c Allergy and Asthma Research Institute   (United States)

^d Allergy and Asthma Associates   (United States)

^e Kerrville Allergy and Asthma   (United States)

^f ALCON RESEARCH LTD   (United States)

^g Central Health Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; DIBENZOXEPIN DERIVATIVE; OLOPATADINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HAY FEVER; HOSPITALIZATION; HUMAN; INTRANASAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ALLERGIC AGENTS; CHILD; DIBENZOXEPINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; RHINITIS, ALLERGIC, SEASONAL; SEVERITY OF ILLNESS INDEX;

EID: 33746615667     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2006.27.2862     Document Type: Article

References (21)

1. Agency for Healthcare. Management of allergic and nonallergic rhinitis. Agency for Healthcare Research and Quality 54:1-6, 2002.
2. Salmun LM, Gates D, Scharf M, et al. Loratadine versus cetirizine: Assessment of somnolence and motivation during the workday. Clin Ther 22:573-582, 2000.
3. Reilly MC, Tanner A, and Meltzer EO. Work, classroom, and activity impairment instruments-Validation studies in allergic rhinitis. Clin Drug Invest 11(5):278-288, 1996.
4. Meltzer EO, Nathan RA, Selner JC, and Storms W. Quality of life and rhinitic symptoms: Results of a nationwide survey with the SF-36 and RQLQ questionnaires. J Allergy Clin Immunol 99(6, part 2):S815-S819, 1997.
5. Craig TJ, McCann JL, Gurevich F, and Davies JJ. The Correlation between allergic rhinitis and sleep disturbance. J Allergy Clin Immunol 114(suppl):S139-S145, 2004.
6. Marshall PS, AND Colon EA. Effects of allergy season on mood and cognitive function. Ann Allergy 71:251-258, 1993.
7. Howard KB, Bowers BW, Cook CK, ET AL. Intranasal fluticasone, loratadine tablets, and their use in combination: An evaluation of economic and humanistic outcomes. Drug Ben Trends October:45-52, 2001.
8. Mann RD, Pearce GL, Dunn N, and Shakir S. Sedation with "non-sedating" antihistamines: Four prescription-event monitoring studies in general practice. Br Med J 320:1184-1187, 2000.
9. Hampel FC, Ratner PH, Amar NJ, et al. Improved quality of life (QoL) among seasonal allergic rhinitis (SAR) patients treated with olopatadine HCl nasal spray, 0.4% and olopatadine HCl nasal spray, 0.6% compared to vehicle. J Allergy Clin Immunol 113:525, 2004.
10. Lanier B, Turner FD, Drake M, et al. Olopatadine Nasal Spray 0.1% reduces the frequency of seasonal allergic rhinitis (SAR) symptoms in patients exposed to high pollen levels. Poster presentation at The Royal Hawaiian Eye Meeting, Hawaii, 2004.
11. Meltzer EO, Hampel FC, Ratner PH, et al. Olopatadine HCL nasal spray is effective and safe for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 92:103, 2004.
12. Ratner PH, Hampel FC, Amar NJ, et al. Olopatadine HCl nasal spray is effective and safe for the treatment of seasonal (mountain cedar) allergic rhinitis. J Allergy Clin Immunol 113(2, suppl 1):S200-S201, 2004.
13. Sanico AM, Bloom C, Reynolds CJ, et al. Olopatadine suppresses nasal allergic reactions. J Allergy Clin Immunol 113(2, suppl 1):S27, 2004.
14. Patel P, Wall GM, Benninger PJ, et al. Dose response, duration, and onset of action of olopatadine nasal spray. Poster presentation at the American Academy of Allergy, Asthma, and Immunology Conference, San Antonio, TX, 05 Mar 22, 2005.
15. Juniper EF, and Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 21:77-83, 1990.
16. Juniper EF, Guyatt GH, Griffith LE, and Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 98:843-844, 1996.
17. Guyatt GH, Juniper EF, Walter SD, et al. Education and debate-Interpreting treatment effects in randomised trials. Br J Med 316:690-693, 1998.
18. Van Cauwenberge P, and Juniper EF and The Star Study Investigating Group. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg, and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 30:891-899, 2000.
19. Lydick E, and Epstein RS. Interpretation of quality of life changes. Qual Life Res 2:221-226, 1993.
20. Crosby RD, Kolotkin RL, and Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 56:395-407, 2003.
21. U.S. Food and Drug Administration (FDA). U.S. Food and Drug Administration Center for Drug Evaluation and Research. 20114S006 Astelin nasal spray medical review, section 9 Overview of Efficacy. 2000.